Results of several ongoing phase I/II clinical trials for RPE65-Leber congenital amaurosis-2 (LCA2) indicate that AAV-mediated Rpe65 delivery to the retinal pigment epithelium (RPE) is both safe and effective [1-4]. The gene discussed is RPE65; the disease is Leber congenital amaurosis 2.